HARVARD BIOSCIENCE INC

For the period ended Dec 31, 2024. Filed Mar 14, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 14, 2025

HBIO$9.26+1.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

HARVARD BIOSCIENCE, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(In thousands)

Accumulated
Number · Additional · Other · Total
	of Shares	Common	Paid-in	Accumulated	Comprehensive	Stockholders’
	Issued	Stock	Capital	Deficit	Loss	Equity
Balance at December 31, 2022	42,082	$454	$229,008	$(142,190)	$(15,052)	$72,220
Stock option exercises	214	-	506	-	-	506
Stock purchase plan	137	-	424	-	-	424
Vesting of restricted stock units	1,460	-	-	-	-	-
Shares withheld for taxes	(498)	-	(2,523)	-	-	(2,523)
Stock-based compensation	-	-	5,000	-	-	5,000
Net loss	-	-	-	(3,415)	-	(3,415)
Other comprehensive income	-	-	-	-	862	862
Other adjustments	-	(20)	20	-	-	-
Balance at December 31, 2023	43,395	434	232,435	(145,605)	(14,190)	73,074
Stock option exercises	14	-	43	-	-	43
Stock purchase plan	161	2	335	-	-	337
Vesting of restricted stock units	769	8	-	-	-	8
Shares withheld for taxes	(265)	(3)	(574)	-	-	(577)
Stock-based compensation	-	-	4,340	-	-	4,340
Net loss	-	-	-	(12,405)	-	(12,405)
Other comprehensive loss	-	-	-	-	(1,480)	(1,480)
Balance at December 31, 2024	44,074	$441	$236,579	$(158,010)	$(15,670)	$63,340

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.